ClouDr Group Limited (HK:9955) has released an update.
ClouDr Group Limited has announced that its subsidiary, Nanjing Polifarma, has filed an application for the market launch of its Vitamin B6 Injection Solution with China’s National Medical Products Administration, which was accepted on June 4, 2024. The product is the first Vitamin B6 solution to pass the country’s consensus evaluation, potentially opening up a significant market opportunity due to priority in clinical applications. The company anticipates this development to boost the long-term growth and benefit its shareholders.
For further insights into HK:9955 stock, check out TipRanks’ Stock Analysis page.
